Login to Your Account

ILC 2018

Alnylam looks to accelerate givosiran to victory lap in AHP

By Marie Powers
News Editor

Monday, April 16, 2018

PARIS – Alnylam Pharmaceuticals Inc. used the International Liver Congress (ILC) as the forum to report solid success in the phase I and I/II open-label extension (OLE) studies of givosiran to treat acute hepatic porphyrias (AHPs), a family of ultra-rare inherited disorders.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription